iBio, Inc.
IBIO Healthcare Biotechnology
In the quarter to June 2026, revenue grew 100.0%, EPS grew 77.4% and free cash flow fell 35.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IBIO
iBio, Inc. (IBIO) EV/Sales
As of 16 October 2026, iBio, Inc. (IBIO) trades at a EV/Sales of −9.7×. Over the past ten years it has ranged from −9.7× (October 2026) to 375× (February 2026) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 141× | 10,053.64% |
| FY2025 | 1.4× | — |
| FY2024 | −2.9× | — |
| FY2022 | 24.8× | (74.60%) |
| FY2021 | 97.5× | 36.26% |
| FY2020 | 71.6× | 330.86% |
| FY2019 | 16.6× | (59.52%) |
| FY2018 | 41.0× | (68.74%) |
| FY2017 | 131× | 105.39% |
| FY2016 | 63.9× | 102.40% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | −6.3× | — |
| Jun 2025 | 1.4× | (96.39%) |
| Dec 2024 | 38.6× | — |
| Jun 2024 | −2.9× | — |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IBIO iBio, Inc. | −9.7× |
| ACET Adicet Bio, Inc. compare | −1.8× |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| TVGN Tevogen Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | 0.6× |
| HOWL Werewolf Therapeutics, Inc. compare | 1.9× |
| HYPD Hyperion DeFi, Inc. compare | 27.9× |
| CLNN Clene Inc. compare | 239× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)